A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
about
ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study3' end mRNA processing: molecular mechanisms and implications for health and diseaseMolecular testing to optimize therapeutic decision making in advanced colorectal cancerPolymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic reviewRecent applications of chemosensitivity tests for colorectal cancer treatmentJapanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical UsePAK6 increase chemoresistance and is a prognostic marker for stage II and III colon cancer patients undergoing 5-FU based chemotherapyMuPIT interactive: webserver for mapping variant positions to annotated, interactive 3D structures.Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer.The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers.ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy.Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer.Thymidine phosphorylase gene variant, platelet counts and survival in gastrointestinal cancer patients treated by fluoropyrimidinesNucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsXeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapyS100A10 protein expression is associated with oxaliplatin sensitivity in human colorectal cancer cellsGlutathione S-transferase Pi expression predicts response to adjuvant chemotherapy for stage C colon cancer: a matched historical control study.The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivityPredictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method.ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomesERCC1 and ERCC2 variants predict survival in gastric cancer patients.EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysisTranslational medicine and reliability of single-nucleotide polymorphism studies: can we believe in SNP reports or not?Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancerPolymorphism in one-carbon metabolism pathway affects survival of gastric cancer patients: Large and comprehensive studyERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting.Association of Environmental Arsenic Exposure, Genetic Polymorphisms of Susceptible Genes, and Skin Cancers in Taiwan.Predictive diagnostics in colorectal cancer: impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy.Polymorphisms of ERCC1 and XRCC1 predict the overall survival of advanced gastric cancer patients receiving oxaliplatin-based chemotherapy.Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin.Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group
P2860
Q21260394-78ACBC57-AF10-4351-B79D-1D2E45CCC8E8Q24648650-69070CDC-7C26-412B-8166-F3E44FEB3952Q26749012-11533990-DF57-40D3-A6CF-B7E71FB8D6C1Q26824719-AAA00D40-96C4-4052-96D9-79B6216088EAQ26851075-F07E5AE3-5D16-42A8-9A11-57B8B4469624Q27851471-2BA3ECFE-09E5-4063-A0A0-5F337FE3D57FQ28068930-222F434C-F8C8-46BB-9A59-736A2153410FQ28252178-9446BD70-F9C7-4D9D-8AC8-A5F08E7151E3Q30432282-C3CE3E6D-DFC1-4ABD-9067-23FF0CF8BAC0Q33337970-F5A851F6-3C2A-4F40-8037-DB813D0075D2Q33383830-1BF5A165-B6B2-45D2-AD8E-DD4148F796A2Q33554403-363D369B-6E82-4560-A034-DCAAFA81C6D5Q33591937-FEC875B5-6D1B-418D-8E7E-A70BE2BFFB23Q33634975-A0EF4421-57C3-479F-BB6D-B5D203EDFB27Q33696582-2EBB0694-2FAA-4AAC-9469-D31B3324D380Q33747440-6A542023-03F4-4F23-8BA1-FEE1303A2892Q33879736-EA1658AB-C796-4EF9-A6B4-89C81F465DFAQ33907209-AE927474-D460-41A5-827C-86D7953CF119Q33985880-8758270C-9E31-412B-9A86-48229B2F75E3Q34008793-F2B2138E-8A1A-42F0-8E45-81373DC48A0FQ34013081-E8EDF021-E2F9-4BBD-B1C8-9373CE9E6E47Q34113977-26019636-6C23-4F3D-941C-E91ECC72DAA4Q34284168-79C5BD80-7F87-4A1B-9C44-ECC63D9AA656Q34676948-2A082BD0-78ED-4586-8AF4-965C5B7F71CDQ34686858-DD191338-2B30-491F-B54B-71EB3815D878Q34694410-1C7E592B-F1A5-4658-8458-DBAB2A9BD3E1Q34902754-25730159-62AB-4708-BD92-E7E83F686A89Q34983863-B8B622E5-C2DE-47EB-925F-B5E229163925Q35146143-D39A146A-35F3-418E-939C-75718C6699F7Q35194655-3418A0E2-CC0C-4840-9583-C14414040FE2Q35196724-264017B8-B7E5-4E7F-9B2E-8A86D8C73129Q35584647-FCA46DE0-5C58-4264-B084-C4E71A12E23EQ35730375-871270C8-4BAF-49F5-9B8B-BF8EBBB6CCE8Q35832445-6C6054A2-DD6C-4D06-8601-1789BB6CF07DQ35833376-A7B3C7B1-B816-4FE0-A700-D1DE3234C3B1Q35941611-AB5D3E02-DB17-4ACA-A9F9-D450AC4B53AFQ36117701-65191CAC-D5FB-4686-B519-A79DAE28E1A5Q36411838-D8D2C614-9A6F-41AE-9335-6D5069F4E895Q36412220-3D13F0DE-1A66-4DBD-AEC5-5D1E9CEB1FC7Q36584224-BE6A7CB0-2045-43E1-A88C-6FF98CB307D3
P2860
A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
A multivariate analysis of gen ...... refractory colorectal cancer.
@ast
A multivariate analysis of gen ...... refractory colorectal cancer.
@en
type
label
A multivariate analysis of gen ...... refractory colorectal cancer.
@ast
A multivariate analysis of gen ...... refractory colorectal cancer.
@en
prefLabel
A multivariate analysis of gen ...... refractory colorectal cancer.
@ast
A multivariate analysis of gen ...... refractory colorectal cancer.
@en
P2093
P2860
P356
P1476
A multivariate analysis of gen ...... refractory colorectal cancer.
@en
P2093
J Stoehlmacher
P2860
P2888
P304
P356
10.1038/SJ.BJC.6601975
P407
P577
2004-07-01T00:00:00Z
P5875
P6179
1020515235